{"entity":{"id":"mds-mpn-response","kind":"term","name":"MDS/MPN international response criteria (2015)","aka":["MDS/MPN response criteria","Savona criteria"],"tldr":"These criteria define response for overlap diseases such as chronic myelomonocytic leukaemia, which have features of both myelodysplastic and myeloproliferative neoplasms.","summary":"Myelodysplastic/myeloproliferative neoplasms in adults have no standard treatment for most patients. An international panel sponsored by the MDS Foundation, through three workshops in 2013 and 2014 (Savona and colleagues, Blood 2015), proposed uniform response criteria for clinical trials that account for both the dysplastic and the proliferative features of these diseases.","asOf":"2026-11-04","links":[{"label":"Savona et al., An international consortium proposal of uniform response criteria for MDS/MPN in adults (Blood 2015)","url":"https://doi.org/10.1182/blood-2014-10-607341"}],"tags":[],"related":["iwg-2023-mds-response"],"cancers":["cmml"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"category":"Endpoints"},"route":"/terms/mds-mpn-response/","neighbours":{"term":[{"id":"complete-response-term","kind":"term","name":"Complete response (CR) and partial response (PR)","route":"/terms/complete-response-term/"},{"id":"iwg-2023-mds-response","kind":"term","name":"IWG 2023 response criteria for higher-risk MDS","route":"/terms/iwg-2023-mds-response/"}],"cancer":[{"id":"cmml","kind":"cancer","name":"Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms","route":"/cancers/cmml/"}]}}